Longevity startup offers AI-powered blood biomarker analysis designed to identify potential health issues at an early stage.
Consumer longevity startup Mito Health has secured an additional $2.2 million in seed funding, bringing its total capital raised to $4 million, as it seeks to enable preventive healthcare through advanced biomarker testing and AI-driven health insights. The company also welcomed renowned longevity researcher Professor Brian Kennedy to its scientific advisory committee.
Based in San Francisco, Mito Health’s platform offers a comprehensive blood-based biomarker analysis, assessing over 100 key indicators related to cardiovascular health, metabolic function, liver health, kidney function and essential nutrients. The data provides a detailed overview of an individual’s health status, helping identify potential issues before they develop into serious conditions.
Mito Health’s focus extends beyond disease prevention to long-term health and longevity. The platform includes risk horizon assessments that project health outcomes over 10, 20 and 30 years based on current lifestyle patterns. Regular reminders and check-ins help users stay aligned with their health goals. The company also integrates data from additional health insights, including DEXA scans and preventative MRIs through partnerships with BodySpec and Prenuvo.
The company says its approach has already yielded results, with 64% of its early customers identifying and addressing elevated health risks, 36% uncovering vitamin or nutrient deficiencies and 4% detecting critical conditions requiring immediate intervention.
“We believe that everyone deserves access to cutting-edge health optimization, and through partnerships, social engagement, and education, we’re bringing longevity science to the mainstream,” said Mito Health co-founder and CEO Kenneth Lou. “As AI continues to advance, our vision of providing ‘an AI doctor in your pocket’ grows ever closer to reality.”
The company’s AI technology translates complex biomarker data into personalized health recommendations. The Mito Health dashboard serves as the central hub for users, offering an intuitive interface to visualize health trends and track progress over time. The platform organizes biomarkers by body system, using color-coded indicators for clarity. It also delivers customized advice across five core health pillars: nutrition, exercise, sleep, supplementation and stress management.
Mito Health’s testing package is priced at $399 and is available across the US. Test results, including a detailed biological age analysis and personalized action plan, are typically delivered within a week. The platform continually updates its recommendations using the latest longevity research, ensuring that health plans remain relevant and evidence-based.
Lou also expressed his excitement at the appointment of National University of Singapore professor Kennedy to the company’s SAB, saying “He brings over 40 years of experience studying the biological processes of aging and developing clocks like LinAge, a blood-based formula for assessing biological age.”
Brian Kennedy, Professor of Biochemistry & Physiology, Yong Loo Lin School of Medicine, NUS
The new funding round was joined by investors including Y Combinator, Capital X, XA Network, Balaji Srinivasan, Nir Eyal, Kevin Aluwi, Nas Daily, Alex Svanevik, Prashanth Prakash and Dhruv Arora. Existing investor Forge Ventures also participated.
“Mito Health has been an incredible partner for my health,” said Monzo co-founder and partner at Y Combinator Tom Blomfield. “In addition to comprehensive bloodwork, Mito Health’s analysis took in all my context including my family medical history, and gave me a clear plan for what to do.”
“It’s been great working with Mito Health,” said Nir Eyal, a New York Times bestselling author. “I especially love the dashboard for tracking my biomarkers over time and seeing long-term trends.”
Mito Health plans to use the new funding to accelerate its growth across the US, enhance its platform capabilities, and expand its range of available tests. The company also aims to unify customer health data into a single platform, offering a more comprehensive view of individual health.
“To develop an AI doctor in your pocket, a client’s health and medical context is essential,” Lou told us. “Hence, we’ll be working on and releasing more features to build towards this direction to be able to pull in all types of health and medical data and organizing it in an approach which makes the most sense for our clients to take action on.”
Photographs courtesy of Mito Health